Nuveen AMT-Free Municipal Credit Income Fund
NVGNASDAQTrading Snapshot
- Day Range
- $12.25 – $12.61
- 52-Week Range
- $249.94 – $550.82
- Volume
- $1.71B
- Avg Volume
- $1.72B
- Shares Outstanding
- 11.42B
- Next Earnings
- Sep 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $215M
- Last Q Revenue
- $115M
- P/E Ratio
- 36.4
- P/S Ratio
- 12.4x
- EPS (TTM)
- $13.65
- Dividend Yield
- 2.45%
Why Investors Own NVG
- ✓High-growth profile — revenue up +8.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Nuveen AMT-Free Municipal Credit Income Fund
NVGAbout Nuveen AMT-Free Municipal Credit Income Fund
A company profile for Nuveen AMT-Free Municipal Credit Income Fund isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting
A Pair Trade Opportunity By Nuveen Municipal Credit Income Funds
I describe a pair trade opportunity between Nuveen AMT-Free Municipal Credit Income Fund and Nuveen Municipal Credit Income Fund to exploit current mispricing. NVG and NZF have very similar, highly correlated portfolios,
NVG: Flirting With A Premium Limits Current Appeal
Nuveen AMT-Free Municipal Credit Income Fund now trades at a slight premium, continuing the trend of tighter valuation. NVG's 7.48% yield is high and getting investors' attention, but it continues to remain significantly
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therape